Skip to main content


Project TitleBiomarkers for Alzheimer's Disease Diagnosis
Track Code3554
Short Description

Cornell Researchers have identified a set of Alzheimer's disease-specific protein biomarkers that can be used in the analysis of cerebrospinal fluid (CSF) to diagnose Alzheimer's disease (AD) patients.



Alzheimer’s disease is the leading cause of dementia amongst the elderly, yet a diagnosis cannot be made until the onset of the disease.  According to the Alzheimer’s Association, in 2016 an estimated 5.2 million of American people age 65 and older have Alzheimer's disease and the number are projected to reach 13.8 million by 2050.  Early detection of AD is essential to a holistic management of the disease (medication to delay the progress, health care cost, etc.). 


The technology developed by Cornell researchers allows for an early diagnostic of AD and comprises:

  1. A panel of specific multiplexed biomarkers in CSF that could be used to quantitatively differentiate between samples from AD patients and from non-AD patients
  2.  An associated database with information on protein expression levels that are and are not associated with AD.


This technology enables early detection of AD, thus allows for adequate treatment strategies.  It has been tested together with a clinical trial of AD therapeutics.  A panel of 23 spots was identified that could be used to differentiate AD and non-AD gels with a sensitivity of 94%, a specificity of 94%, and a predicted classification error rate of only 5.9%. The figure below. shows the ability of the biomarkers panel to isolate AD from non-AD patients amongst 68 cerebrospinal fluid samples).



Potential Applications

Early diagnostic test for Alzheimer's disease.



  • An early diagnostic test would eliminate false positives, allowing doctors to explore disease possibilities other than AD.
  • This diagnostic method is comprehensive, compared to existing methods that must employ several different tests to detect AD.
  • The diagnostics can be done using ELISA and other techniques.


TagsCNS & PNS, Diseases & Treatment Areas, life science, Proteomics-based specific tests, medical diagnostics (in vitro), molecular diagnostics
Posted DateJul 24, 2012 7:55 PM


Kelvin Lee
Erin Finehout
Norman Relkin

Additional Information

  • U.S. Patent 9,335,331
  • Choi Y, Choe LH, Lee KH (2010). Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. Expert Review of Proteomics 7: 919-926. PMID: 21142892. DOI: 10.1586/epr.10.75
  • Finehout E.J., et al. (2007). Cerebrospinal Fluid Proteomic Biomarkers for Alzheimer's Disease. Annals of Neurology 61, 120-129. DOI: 10.1002/ana.21038
  • Choe L, et al. (2007). 8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer’s disease. Proteomics 7(20):3651-3660. DOI: 10.1002/pmic.200700316.

Licensing Contact

Phillip Owh


File Name Description
Technology brief D3554 Method of Diagnosis AD Download